To evaluate the safety of stimulants in children with epilepsy.
Methods:
In a retrospective cohort study based on Medicaid Analytic eXtract billing records from 26 U.S. states from 1999 to 2010, we identified incident stimulant use among children with epilepsy through outpatient encounter claims and pharmacy claims. We established a control group of nonusers and used frequency matching to generate index dates. We followed both cohorts for 12 months and calculated hazard ratios [HRs] of current and former use of stimulants versus no use on the outcome of seizure-related hospitalization using multivariate Cox proportional hazard models.
Results:
We identified 18,166 stimulant users and 54,197 nonusers in children with epilepsy. The incidence of seizure-related hospitalization in current stimulant users, former users, and nonusers was 3.6, 3.5, and 4.3 per 100 patient-years. After adjustment for confounders, we found current and former use of stimulants did not increase seizure-related hospitalizations (HR 0.95, 95% confidence interval [CI]: 0.83, 1.09 and HR 0.99, 95% CI: 0.85, 1.15). Children with cerebral palsy, congenital nervous system anomalies, or intellectual disability did not have significantly higher HRs than those without the already mentioned comorbidities.
Conclusion:
This study has not identified any overall increase in the rate of seizure-related hospitalizations with the use of stimulants in children with epilepsy.
Get full access to this article
View all access options for this article.
References
1.
AustinPC: An introduction to propensity score methods for reducing the effects of confounding in observational studies. Multivariate Behav Res, 46:399–424, 2011.
CohenR, SeneckyY, ShuperA, InbarD, ChodickG, ShalevV, RazR: Prevalence of epilepsy and attention-deficit hyperactivity (ADHD) disorder: A population-based study. J Child Neurol, 28:120–123, 2013.
7.
FeldmanH, CrumrineP, HandenBL, AlvinR, TeodoriJ: Methylphenidate in children with seizures and attention-deficit disorder. Am J Dis Child, 143:1081–1086, 1989.
8.
FosiT, Lax-PericallMT, ScottRC, NevilleBG, AylettSE: Methylphenidate treatment of attention deficit hyperactivity disorder in young people with learning disability and difficult-to-treat epilepsy: Evidence of clinical benefit. Epilepsia, 54:2071–2081, 2013.
9.
Gonzalez-HeydrichJ, WhitneyJ, WaberD, ForbesP, HsinO, FaraoneSV, DoddsA, RaoS, MrakotskyC, MacmillanC, DemasoDR, de MoorC, TorresA, BourgeoisB, BiedermanJ: Adaptive phase I study of OROS methylphenidate treatment of attention deficit hyperactivity disorder with epilepsy. Epilepsy Behav, 18:229–237, 2010.
10.
GordonE, DevinskyO: Alcohol and marijuana: Effects on epilepsy and use by patients with epilepsy. Epilepsia, 42:1266–1272, 2001.
11.
Gross-TsurV, ManorO, van der MeereJ, JosephA, ShalevRS: Epilepsy and attention deficit hyperactivity disorder: Is methylphenidate safe and effective?. J Pediatr, 130:670–674, 1997.
12.
GucuyenerK, ErdemogluAK, SenolS, SerdarogluA, SoysalS, KockarAI: Use of methylphenidate for attention-deficit hyperactivity disorder in patients with epilepsy or electroencephalographic abnormalities. J Child Neurol, 18:109–112, 2003.
JetteN, ReidAY, QuanH, HillMD, WiebeS: How accurate is ICD coding for epilepsy?. Epilepsia, 51:62–69, 2010.
15.
KangKD, YunSW, ChungU, KimTH, ParkJH, ParkIH, HanDH: Effects of methylphenidate on body index and physical fitness in Korean children with attention deficit hyperactivity disorder. Hum Psychopharmacol, 31:76–82, 2016.
16.
KoneskiJA, CasellaEB, AgerttF, FerreiraMG: Efficacy and safety of methylphenidate in treating ADHD symptoms in children and adolescents with uncontrolled seizures: A Brazilian sample study and literature review. Epilepsy Behav, 21:228–232, 2011.
17.
KoppelBS, SamkoffL, DarasM: Relation of cocaine use to seizures and epilepsy. Epilepsia, 37:875–878, 1996.
18.
LeonardCE, BilkerWB, NewcombC, KimmelSE, HennessyS: Antidepressants and the risk of sudden cardiac death and ventricular arrhythmia. Pharmacoepidemiol Drug Saf, 20:903–913, 2011.
19.
LeonardCE, FreemanCP, NewcombCW, BilkerWB, KimmelSE, StromBL, HennessyS: Antipsychotics and the risks of sudden cardiac death and all-cause death: Cohort studies in medicaid and dually-eligible medicaid-medicare beneficiaries of five states. J Clin Exp Cardiolog Suppl, 10:1–9, 2013.
20.
ManjunathR, ParadisPE, PariseH, LafeuilleMH, BowersB, DuhMS, LefebvreP, FaughtE: Burden of uncontrolled epilepsy in patients requiring an emergency room visit or hospitalization. Neurology, 79:1908–1916, 2012.
MTA Group: A 14-month randomized clinical trial of treatment strategies for attention-deficit/hyperactivity disorder. The MTA Cooperative Group. Multimodal Treatment Study of Children with ADHD. Arch Gen Psychiatry, 56:1073–1086, 1999a.
23.
MTA Group: Moderators and mediators of treatment response for children with attention-deficit/hyperactivity disorder: The multimodal treatment study of children with attention-deficit/hyperactivity disorder. Arch Gen Psychiatry, 56:1088–1096, 1999b.
24.
PearsonDA, SantosCW, AmanMG, ArnoldLE, CasatCD, MansourR, LaneDM, LovelandKA, BuksteinOG, JergerSW, FactorP, VanwoerdenS, PerezE, ClevelandLA: Effects of extended release methylphenidate treatment on ratings of attention-deficit/hyperactivity disorder (ADHD) and associated behavior in children with autism spectrum disorders and ADHD symptoms. J Child Adolesc Psychopharmacol, 23:337–351, 2013.
25.
RadziukAL, KielingRR, SantosK, RotertR, BastosF, PalminiAL: Methylphenidate improves the quality of life of children and adolescents with ADHD and difficult-to-treat epilepsies. Epilepsy Behav, 46:215–220, 2015.
26.
RaviM, IckowiczA: Epilepsy, attention-deficit/hyperactivity disorder and methylphenidate: Critical examination of guiding evidence. J Can Acad Child Adolesc Psychiatry, 25:50–58, 2016.
27.
ReidAY, St. Germaine-SmithC, LiuM, SadiqS, QuanH, WiebeS, FarisP, DeanS, JettéN: Development and validation of a case definition for epilepsy for use with administrative health data. Epilepsy Res, 102:173–179, 2012.
28.
ReillyC, AtkinsonP, DasKB, ChinRF, AylettSE, BurchV, GillbergC, ScottRC, NevilleBG: Neurobehavioral comorbidities in children with active epilepsy: A population-based study. Pediatrics, 133:e1586–1593, 2014.
29.
RossME, KreiderAR, HuangYS, MatoneM, RubinDM, LocalioAR: Propensity score methods for analyzing observational data like randomized experiments: Challenges and solutions for rare outcomes and exposures. Am J Epidemiol, 181:989–995, 2015.
30.
RussSA, LarsonK, HalfonN: A national profile of childhood epilepsy and seizure disorder. Pediatrics, 129:256–264, 2012.
31.
SantosK, PalminiA, RadziukAL, RotertR, BastosF, BooijL, FernandesBS: The impact of methylphenidate on seizure frequency and severity in children with attention-deficit-hyperactivity disorder and difficult-to-treat epilepsies. Dev Med Child Neurol, 55:654–660, 2013.
32.
Semrud-ClikemanM, WicalB: Components of attention in children with complex partial seizures with and without ADHD. Epilepsia, 40:211–215, 1999.
33.
ShangCY, PanYL, LinHY, HuangLW, GauSS: An open-label, randomized trial of methylphenidate and atomoxetine treatment in children with attention-deficit/hyperactivity disorder. J Child Adolesc Psychopharmacol, 25:566–573, 2015.
34.
ShcherbakovaN, RascatiK, BrownC, LawsonK, NovakS, RichardsKM, YoderL: Factors associated with seizure recurrence in epilepsy patients treated with antiepileptic monotherapy: A retrospective observational cohort study using US administrative insurance claims. CNS drugs, 28:1047–1058, 2014.
35.
ShinnarS, PellockJM: Update on the epidemiology and prognosis of pediatric epilepsy. J Child Neurol, 17Suppl 1:S4–S17, 2002.
36.
SinghiP: Infectious causes of seizures and epilepsy in the developing world. Dev Med Child Neurol, 53:600–609, 2011.
37.
SlamaH, FeryP, VerheulpenD, VanzeverenN, Van BogaertP: Cognitive improvement of attention and inhibition in the late afternoon in children with attention-deficit hyperactivity disorder (ADHD) treated with osmotic-release oral system methylphenidate. J Child Neurol, 30:1000–1009, 2015.
38.
StevensJR, WilensTE, SternTA: Using stimulants for attention-deficit/hyperactivity disorder: Clinical approaches and challenges. Prim Care Companion CNS Disord, 15:PCC12f01472, 2013.
39.
The National Pharmaceutical Council, Inc.: Pharmaceutical Benefits Under State Medical Assistance Programs. Reston, VA, National Pharmaceutical Council. 2007.
40.
TorresAR, WhitneyJ, Gonzalez-HeydrichJ: Attention-deficit/hyperactivity disorder in pediatric patients with epilepsy: Review of pharmacological treatment. Epilepsy Behav, 12:217–233, 2008.
WilliamsAE, GiustJM, KronenbergerWG, DunnDW: Epilepsy and attention-deficit hyperactivity disorder: Links, risks, and challenges. Neuropsychiatr Dis Treat, 12:287–296, 2016.
43.
WroblewskiBA, LearyJM, PhelanAM, WhyteJ, ManningK: Methylphenidate and seizure frequency in brain injured patients with seizure disorders. J Clin Psychiatry, 53:86–89, 1992.
44.
YatsugaC, ToyohisaD, FujisawaTX, NishitaniS, ShinoharaK, MatsuuraN, IkedaS, MuramatsuM, HamadaA, TomodaA: No association between catechol-O-methyltransferase (COMT) genotype and attention deficit hyperactivity disorder (ADHD) in Japanese children. Brain Dev, 36:620–625, 2014.
45.
YooHK, ParkS, WangHR, LeeJS, KimK, PaikKW, YumMS, KoTS: Effect of methylphenidate on the quality of life in children with epilepsy and attention deficit hyperactivity disorder: And open-label study using an osmotic-controlled release oral delivery system. Epileptic Disord, 11:301–308, 2009.
46.
ZagnoniPG, AlbanoC: Psychostimulants and epilepsy. Epilepsia, 43Suppl 2:28–31, 2002.
Supplementary Material
Please find the following supplemental material available below.
For Open Access articles published under a Creative Commons License, all supplemental material carries the same license as the article it is associated with.
For non-Open Access articles published, all supplemental material carries a non-exclusive license, and permission requests for re-use of supplemental material or any part of supplemental material shall be sent directly to the copyright owner as specified in the copyright notice associated with the article.
